TVM Capital Life Science closes Fund VII at $202 mln
TVM Capital Life Science, a global venture capital firm with an office in Montréal, has closed its TVM Life Science Ventures VlI. Focusing on achieving human clinical proof-of-concept for early-stage drug development projects, Fund VII raised US$201.6 million from cornerstone investors Teralys Capital and Eli Lilly and Co, as well as the Business Development Bank of Canada (BDC), Minnesota Life Insurance Co, CD Venture, Fondaction CSN and a number of pharmaceutical companies. Fund VII targets 12 to 15 project-focused-companies and up to five traditional, syndicated venture capital investments. Earlier this year, it invested in Montréal's PRCL Research Inc, a special purpose company that develops pharmaceutical assets.
6 October 2014•5 mins read
